Most Popular
Research Trends
Beyond Obesity Research: B6-hGDF15 Humanized Mice for Tumor, Diabetes, Morning Sickness, and Cardiovascular Studies
Jun 17, 2024
Obesity is a major global health issue, and the discovery of new targets and the development of new therapies have always been focal points for researchers and pharmaceutical companies. Read More >
Research Trends
Inflammatory Bowel Disease Research Model—BALB/c-Il10 KO Mice for Studying Crohn's Disease & Ulcerative Colitis
Jun 11, 2024
The recent news that Kate Middleton, the Duchess of Cambridge, might be suffering from Crohn's Disease (CD) has drawn widespread public attention, leading more people to become aware of this condition, often referred to as "green cancer." Read More >
Research Trends
Next-Generation Humanized Models Construction Technology: TurboKnockout®
May 31, 2024
There are typically two techniques used for the genetic modification of mice: embryonic steam (ES) targeting and CRISPR. Read More >
The Value of hTTR & hTTR V50M Humanized Mice in Developing Therapies for Transthyretin Amyloidosis
May 24, 2024
A leading RNAi therapy company, Alnylam, recently disclosed its performance results for 2023, which revealed that its two siRNA drugs targeting transthyretin (TTR) for the treatment of amyloidosis, patisiran and vutrisiran, collectively generated sales exceeding $913 million. Read More >
Research Trends
Can B6-hIGHMBP2 Humanized Mice Offer a Breakthrough for Spinal and Peroneal Muscular Atrophy Research?
May 17, 2024
On January 23, 2024, Vanda Pharmaceuticals (VNDA) announced that its antisense nucleotide (ASO) drug VCA-894A targeting the IGHMBP2 gene has officially received FDA's Investigational New Drug (IND) approval. Read More >
Research Trends
Humanized Model for Therapeutic Targets of Parkinson's Disease Dementia: B6-hSNCA Mice
May 11, 2024
In this issue, we introduce the genetically humanized SNCA model - B6-hSNCA mouse (product number: C001427), providing a next-generation humanized mouse model for drug discovery for the key therapeutic target of Parkinson's Disease (PD) & Dementia with Lewy Bodies (DLB). Read More >
Research Trends
Psoriasis Targeted Drug Evaluation Model—B6-hIL-17A Mice
Apr 26, 2024
In this issue, we introduce the Psoriasis Targeted Drug Evaluation Model—B6-hIL-17A Humanized Mice, which provides an improved platform for preclinical disease modeling of psoriasis treatments for effective and efficient clinical translation. Read More >
Research Trends
Spinocerebellar Ataxia Type III (SCA3) Research Model—B6-hATXN3 Mice
Apr 19, 2024
This issue introduces the Spinocerebellar Ataxia Type III (SCA3) research mouse model—B6-hATXN3 mice (Product Number: C001398). Moreover, B6-hATXN3 mice exclusively express the human gene - unlike the common B6-TG(ATXN3-84Q) mice, which express both the human ATXN3 gene and the mouse Atxn3 gene. Read More >
Research Trends
Amyotrophic Lateral Sclerosis (ALS) TDP-43 Proteinopathy Research Model - B6-hTARDBP Mice
Apr 16, 2024
This issue introduces the TDP-43 proteinopathy research model - B6-hTARDBP mice (Product Number: C001418). In amyotrophic lateral sclerosis (ALS), pathological abnormalities of TDP-43 protein are almost universally present, regardless of whether the TARDBP gene is mutated. Read More >
Research Trends
Suitable Preclinical Atherosclerosis Research Model: B6J-Apoe Knockout Mice
Apr 03, 2024
In this issue, we introduce the B6J-Apoe knockout (KO) mouse model for atherosclerosis research. Atherosclerosis, a specific type of arteriosclerosis, is a chronic immune-metabolic inflammatory disease that causes the buildup of fats, cholesterol and other substances on the artery walls. Read More >